Lower the risks of the pharmaceutical drug development process!

NemaLife identified key gaps in the drug discovery and preclinical testing phases that cannot be addressed affordably using current methods. We developed a platform that more realistically models the human population. Screening with our technology from the beginning or testing candidates in the pre-IND discovery phase potentially reduces the unforeseen toxicity and lack of efficacy issues during clinical trials.


Approximately 88% of drugs tested with currently available assays fail after entering clinical trials, and 80% of the failures are due to unforeseen toxicity or lack of efficacy.

Scientific Publications

NemaLife chip: a micropillar-based microfluidic culture device optimized for aging studies in crawling C. elegans.

NemaFlex: a microfluidics-based technology for standardized measurement of muscular strength of C. elegans.

Tart Cherry Increases Lifespan in Caenorhabditis elegans by Altering Metabolic Signaling Pathways.

Senotherapeutic peptide reduces skin biological age and improves skin health markers

Effect of cannabidiol on the long-term toxicity and lifespan in the pre-clinical model Caenorhabditis elegans 

Pharmaceuticals FAQ

If my company orders a study through the screening service, how soon could we expect to receive the results?


Study time varies with volume and the type of testing ordered.
A typical whole-life study lasts about 6 weeks, short term and stress assays take about 2 weeks, including report writing.

I've heard about C elegans screening services in the past. What makes NemaLife different?


Our proprietary technology creates a highly sensitive, immersive testing environment, which allows us to test drugs at comparable concentrations to in-vitro and in vivo mammalian models. In addition, we offer multifactorial diversity assays that no other routine preclinical model currently offer.

pharmaceutical .png